CSL Limited (CSL Behring) CEO Net Worth

Last Updated Mar 10, 2025
CEO NamePaul McKenzie
NationalityUnited Kingdom
Net Worth Estimation$25 million

Paul McKenzie's estimated net worth of around $25 million USD comes primarily from his executive compensation, stock options, bonuses, and long-term equity incentives received as CEO of CSL Limited (CSL Behring), a global biotechnology company with significant annual revenues. Public filings and industry reports support this estimate by factoring in current shareholdings, past earnings, and market performance of CSL Limited.

Paul McKenzie, CEO of CSL Limited (CSL Behring), has an estimated net worth of $25,000,000, which is 25% of the category's $90,000,000 maximum and 150% above its $10,000,000 minimum. This places his net worth solidly between the minimum and maximum estimated for healthcare CEOs.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Paul McKenzie Performance in CSL Limited (CSL Behring)

Paul McKenzie, CEO of CSL Limited (CSL Behring), demonstrates strategic leadership by driving innovation and operational excellence in the biopharmaceutical sector. His decisive approach focuses on expanding global market presence and enhancing research and development capabilities, resulting in robust financial performance and product pipeline growth. Under McKenzie's leadership, CSL has strengthened its industry position, delivering consistent shareholder value and advancing life-saving therapies worldwide.


Latest News

CSL Limited's 2025 Financial Growth and CEO Paul McKenzie's Strategic Initiatives

CSL Limited, led by CEO Paul McKenzie since March 2023, announced a 14% profit increase reaching $3.3 billion in net profit for FY 2025, driven by strong demand for plasma therapies at CSL Behring. McKenzie revealed plans to spin off the vaccine division, cut up to 15% workforce, and streamline operations to boost pipeline productivity and simplify the business amidst market challenges. Despite strong results, CSL shares fell due to investor concerns about margins and US market uncertainties.
Source: http://www.cslbehring.de/en-us/news/2025/jahresergebnisse-2025



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about CSL Limited (CSL Behring) are subject to change from time to time.

Comments

No comment yet